MS crystal ball: new biomarkers aim to predict disability before it strikes

NCT ID NCT05622643

Ongoing Knowledge-focused Sponsor: EDMUS Foundation Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study follows 300 people with multiple sclerosis to see whether advanced MRI scans, eye tests, and blood markers can better predict when disability will worsen. Current tools are not accurate enough to guide early treatment for each individual. The researchers will compare these new biomarkers with standard measures to find which ones best forecast physical or cognitive decline over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which MS patients are at risk of worsening disability, enabling earlier and more personalized treatment decisions.
What could go wrong: This is an observational study, not a treatment trial. The biomarkers may not prove accurate enough to change clinical practice, and results may take years to validate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Locations

CHU de Lyon

Lyon, France
CHU de Nancy

Nancy, France
CHU de Nîmes

Nîmes, France
CHU de Rennes

Rennes, France
CHU de Strasbourg

Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.